Compositions and methods for activation of NK cells killing of prostate cancer and breast cancer cells
AssigneeUniversity of North Texas Health Science Center
InventorsPurunelloor A. Mathew, Stephen O. Mathew
Life of this patent
Estimating the term…
Abstract
Certain embodiments are directed to methods of treating LLT1 expressing cancer by administering to a subject having an LLT1 expressing cancer an LLT1 inhibitor.
Claims22
A method for treating breast cancer or prostate cancer in a patient in need of such treatment, comprising administering to the patient an antibody or antibody fragment that binds LLT1, the antibody or antibody fragment comprising heavy chain complementarity-determining regions (CDRs) having an amino acid sequence of SEQ ID NO:11, SEQ ID NO:12, and SEQ ID NO:13, and light chain CDRs having an amino acid sequences of SEQ ID NO:15, SEQ ID NO:16, and SEQ ID NO:17, wherein the antibody or antibody fragment binds to cancer cells and inhibits cancer growth or progression.
An anti-LLT1 antibody comprising heavy chain CDRs having an amino acid sequence of SEQ ID NO:11, SEQ ID NO:12, and SEQ ID NO:13, and light chain CDRs having an amino acid sequence of SEQ ID NO:15, SEQ ID NO:16, and SEQ ID NO:17, wherein the antibody binds to cancer cells and inhibits cancer growth or progression.
Dependencies are inferred from the claim text.